323990 — Vaxcell Bio Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- KR₩324bn
- KR₩277bn
- KR₩14m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1,254 | -3,984 | -4,763 | -6,825 | -10,274 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | -1,980 | 560 | 270 | 291 | -127 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -540 | -64.6 | -427 | 178 | 578 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -3,589 | -3,303 | -4,662 | -6,045 | -9,423 |
Capital Expenditures | -903 | -31.9 | -2,228 | -290 | -199 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 2,975 | -20,017 | -1,009 | 4,624 | -51,588 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 2,073 | -20,049 | -3,237 | 4,333 | -51,787 |
Financing Cash Flow Items | — | — | -86.8 | — | -1,174 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1,145 | 29,180 | 305 | -208 | 69,866 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -372 | 5,828 | -7,594 | -1,919 | 8,657 |